2017
MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis
Sahu A, Jha P, Prabhakar A, Singh H, Gupta N, Chatterjee T, Tyagi T, Sharma S, Kumari B, Singh S, Nair V, Goel S, Ashraf M. MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis. EBioMedicine 2017, 26: 175-186. PMID: 29217135, PMCID: PMC5832640, DOI: 10.1016/j.ebiom.2017.11.022.Peer-Reviewed Original ResearchConceptsMiR-145 levelsTissue factorVenous thromboembolismMiR-145Thrombus formationTF levelsTargeting tissue factorPromising therapeutic strategyCardiovascular complicationsThrombus loadVenous thrombosisCoagulation variablesPreclinical findingsTherapeutic strategiesVT patientsTF expressionInverse correlationKey moleculesPatientsVivo experimentsUndescribed roleTarget genesVTThromboembolismLevels
2016
Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population
Kumari B, Prabhakar A, Sahu A, Chatterjee T, Tyagi T, Gupta N, Nair V, Ashraf M. Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population. Clinical And Applied Thrombosis/Hemostasis 2016, 23: 429-437. PMID: 27481876, DOI: 10.1177/1076029616661416.Peer-Reviewed Original ResearchConceptsVenous thromboembolismGene polymorphismsEndothelin-1Plasma levelsHealthy controlsG polymorphismOccurrence of VTEEnzyme (ACE) I/DEndothelial nitric oxide synthaseIndian populationEndothelin-1 gene polymorphismsLogistic regression model analysisEnzyme-linked immunoassay kitNitric oxide synthaseRegression model analysisEndothelial functionClinical progressionVascular functionOxide synthaseG alleleSignificant associationIndividual susceptibilityImmunoassay kitPatientsThromboembolism
2015
Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action
Rashid Q, Abid M, Gupta N, Tyagi T, Ashraf M, Jairajpuri M. Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action. BioMed Research International 2015, 2015: 630482. PMID: 25866798, PMCID: PMC4381846, DOI: 10.1155/2015/630482.Peer-Reviewed Original ResearchConceptsFavorable safety profileNovel anticoagulant agentsForm of heparinAnticoagulant administrationSafety profileAntithrombotic agentsAnticoagulant agentsAnticoagulant factorsHemostatic balanceAntithrombotic potentialLow doseAntiplatelet mechanismFibrinolytic systemPlatelet aggregationThrombotic ratsFirst lineHeparinCoagulation timeRatsBlood plasmaNovel compoundsThromboembolismComplicationsAnticoagulantsTherapy